QIBA Proton Density Fat Fraction Biomarker Committee (BC) Update Call
Thursday, February 1, 2018 at 3 PM (CT)
Call Summary

Participants
Scott Reeder, MD, PhD (Co-chair)  Diego Hernando, PhD  Suraj Serai, PhD
Takeshi Yokoo, MD, PhD (Co-chair)  Jonathan Riek, PhD  Claude Sirlin, MD
Gavin Hamilton, PhD  Matthew Robson, PhD
RSNA  Joe Koudelik  Susan Weinmann

Review of Previous Call Summary
- The 01.04.2018 call summary was approved as presented

Profile
- Dr. Yokoo (Philips) prepared a list of protocols with help from Drs. Hernando (GE) and Bashir (Siemens), consolidating details into a reference table
- Discrepancies were found across vendors
  - Some terminology differences identified for similar items, parameters, or features
  - Harmonization of naming conventions across vendors for all critical parameters recommended
  - Footnotes to be added
  - Suggestion to highlight vendor-specific options (non-common parameter setting) that are loaded/not changeable on scanners
- Both “default value” / “recommended range” columns for each vendor included in table
- The “recommended range” for Field of View (FOV) originated from PDFF BC, not from the vendor
- Volunteers to refine MRI PDFF Protocols at 1.5T (3D PDFF Product Sequences) table were requested; Dr. Serai to help with Siemens, Dr. Hernando with GE and Dr. Yokoo with Philips

Profile Conformance Requirement
- It was agreed that phantom testing alone was not adequate; a repeatability study with human subjects was recommended
- Discussion on MRS vs. MRI in regard to bias and variability
- Linearity and Bias testing shall be performed by:
  - Two independent studies with 25 patients using same machine (no machine variability) or one study with 50 patients; Dr. Obuchowski to be consulted on study design
  - Exploring how using different scanners affects bias and repeatability; Dr. Obuchowski to be consulted on study design
  - Scan-rescan experiment by complete removal of the subject from the magnet prior to rescanning
• Discussion on criteria for QIBA Claims, if MRS will not be used; any method will have a similar risk of Alpha Errors (type 1 errors):
  o 1. Human testing for repeatability (i.e. in vivo testing)
  o 2. MRS or MRI that has been previously validated by MRS in vivo
  o 3. Standard Reference Object for Bias (i.e. Phantom)
    ▪ Phantoms may help identify imaging sites that implement the Profile correctly, i.e., conformant sites
    ▪ Fat-water phantoms with known PDFF values using phantom-specific recon protocol helpful but may not be sufficient (i.e. human studies needed)
    ▪ Additional discussion needed regarding range of fat fractions

• Dr. Yokoo to circulate Profile draft for review

Next call: Thursday, March 1, 2018 at 3 PM CT

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible. Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries.